리제네론사의 코로나19 항체치료제 임상3상 결과
investor.regeneron.com/news-releases/news-release-details/phase-3-trial-shows-regen-covtm-casirivimab-imdevimab-antibody Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-h TARRYTOWN, N.Y. , March 23, 2021 /PRNewswire/ -- REGEN-COV also significantly shortened the duration of symptoms by 4 days All doses (8,000 mg, 2,400 ..
코로나19 팬데믹
2021. 3. 25. 11:12